PYC Therapeutics Limited

PYC

AU000000PYC7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-19 am EDT			5-day change	1st Jan Change
0.091 ^AUD	-4.21%		-5.21%	-17.27%

Apr. 10	PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	MT
Mar. 18	PYC Therapeutics Raises AU$40 Million via Entitlement Offer	MT

Rights Issue: 0.1 new shares @ 0.17 AUD for 1 existing share

October 21, 2020

Latest news about PYC Therapeutics Limited

PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	Apr. 10	MT
PYC Therapeutics Raises AU$40 Million via Entitlement Offer	Mar. 17	MT
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates	Mar. 14	MT
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	Feb. 16	MT
Transcript : PYC Therapeutics Limited - Special Call	Feb. 01
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	Jan. 01	MT
Transcript : PYC Therapeutics Limited - Shareholder/Analyst Call	Nov. 23
Transcript : PYC Therapeutics Limited - Special Call	Nov. 16
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	Nov. 13	CI
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	Nov. 03	MT
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	23-10-05	MT
Transcript : PYC Therapeutics Limited - Special Call	23-10-04
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	23-09-22	MT
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	23-08-11	CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%	23-08-09	MT
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	23-08-01	MT
PYC Therapeutics Completes Toxicology Testing of Retinitis Pigmentosa Medication	23-07-18	MT
PYC Therapeutics Doses First Patient in Blinding Eye Disease Trial	23-06-29	MT
Pyc Appoints Andrew Taylor as Joint Company Secretary	23-06-01	CI
PYC Therapeutics to Raise AU$30 Million in Placement	23-05-11	MT
PYC Therapeutics Halts Trade Ahead of Capital Raising Announcement	23-05-10	MT
PYC Therapeutics Secures US FDA Clearance to Start Retinitis Pigmentosa Trial	23-03-06	MT
Us Fda Clears PYC Therapeutics Limited to Commence the First Ever Human Trial in Retinitis Pigmentosa Type 11	23-03-05	CI

Chart PYC Therapeutics Limited

Duration

Period

More charts

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company, which offers ribonucleic acid (RNA) therapeutics in patients with unmeet genetic diseases. The Company has RNA targeted therapeutics design capabilities to deliver technologies based on cell penetrating peptides (CPPs) and peptide conjugated phosphorodiamidate morpholino oligomer (PPMOs). The Company develops a pipeline of therapies, including two programs, which are focused on inherited eye diseases and preclinical discovery programs, which are focused on neurodegenerative and kidney diseases. The Companyâs lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate PYC-001, which is focused on treating autosomal dominant optic atrophy (ADOA). Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PYC Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.095 AUD

Average target price

0.345 AUD

Spread / Average Target

+263.16%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PYC THERAPEUTICS LIMITED	-17.27%	274M
IQVIA HOLDINGS INC.	-1.27%	41.35B
LONZA GROUP AG	+41.82%	40.38B
MODERNA, INC.	+3.44%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+2.24%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-23.42%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.98%	11.68B
MEDPACE HOLDINGS, INC.	+21.24%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.80%	11.15B

Other Biotechnology & Medical Research

PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Biotechnology & Medical Research

Rights Issue: 0.1 new shares @ 0.17 AUD for 1 existing share

Latest news about PYC Therapeutics Limited

Chart PYC Therapeutics Limited

Company Profile

Income Statement Evolution

Ratings for PYC Therapeutics Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research